Ablynx expands into new r&d facilities

Published: 23-Jun-2010
Ingredients Research & Development

The Belgium-based company is leasing new r&d facilities on the Technologiepark near Ghent


Belgium-based biopharmaceutical company Ablynx has moved into new r&d facilities located on the Technologiepark in Zwijnaarde, near Ghent.

The company is leasing 8,000 m2 of the brand new 10,000 m2 building which is located on the same Technologiepark as Ablynx's previous facilities.

‘This new cutting-edge laboratory building will support Ablynx's growth in the foreseeable future. This allows us to house our Belgian operations in one facility’, said Dr Edwin Moses, chief executive officer and chairman of Ablynx. ‘With over 240 staff we believe Ablynx is one of the most advanced independent, next-generation biologics companies.’

Founded in 2001 in Ghent, Belgium, Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease.

See more

You may also like

Research & Development

Sanofi to acquire Ablynx for €3.9 billion

Read more
The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  5. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Sanofi to acquire Ablynx for €3.9 billion

The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules
Research & Development

Novel Nanobody to begin clinical development in osteoarthritis

Ablynx to receive €15m milestone payment from Merck
Ingredients

Ablynx acheives first milestone as part of collaboration with Novo Nordisk

Multi-specific nanobody candidate reaches discovery milestone
Regulatory

Ablynx to receive an €8m milestone payment as Boehringer Ingelheim starts a Phase I study with an anti-CX3CR1 nanobody

The anti-CX3CR1 nanobody was discovered and developed as part of a longstanding strategic alliance between both parties
Research & Development

Ablynx to work with Novo Nordisk on nanobody drug discovery

Will receive a €5m upfront payment, research funding and potential future milestones and royalties on net sales
Research & Development

Ablynx enters €13m immuno-oncology collaboration expansion with Merck

Takes responsibility for the discovery and development of up to 12 additional Nanobody programmes
Research & Development

Ablynx and Taisho Pharmaceutical enter agreement to develop rheumatoid arthritis drug in Japan

Ablynx will receive an upfront payment of US$3m
Subscribe now